Canopy Growth vs. Curaleaf: Which Cannabis Stock Is a Better Buy?

: CGC | Canopy Growth Corporation  News, Ratings, and Charts

CGC – Canopy Growth (CGC) is a Canadian cannabis company that is grappling with big losses and decelerating top-line growth. In contrast, U.S.-based cannabis enterprise (CURLF) has enjoyed strong sales, allowing it to consistently post positive EBITDA. The important question now is which of these stocks has better prospects. Read on.

Two year ago, Canopy Growth (CGC) was a pot stock to watch after Canada legalized cannabis at the federal level for medical and recreational use. However, since the start of 2019, shares of Canopy Growth have been range bound and have grossly underperformed the broader market. The company has returned just 2% over this period. In comparison,  U.S.-based Curaleaf (CURLF) has seen its stock price more than triple since January 2019.

Smiths Falls, Canada-based Canopy Growth Corporation (CGC), grows and sells medical cannabis in Canada. Its products include dried flowers, oils and concentrates, soft gel capsules, and hemps. The company offers its products under the Tweed, Black Label, Spectrum Cannabis, DNA Genetics, Leafs By Snoop, Bedrocan Canada, CraftGrow, and Foria brand names. It also offers its products through Tweed Main Street, a single online platform that enables registered patients to purchase medicinal cannabis from various producers across various brands.

Curaleaf Holdings, Inc., (CURLF), which is based in Wakefield, Massachusetts, operates as an integrated medical and wellness cannabis operator in the United States. It operates in two segments: Cannabis Operations and Non-Cannabis Operations. Its  Cannabis Operations segment produces and sells cannabis through retail and wholesale channels. Its Non-Cannabis Operations segment provides professional services, including cultivation, processing, retail know-how and back-office administration, intellectual property licensing, real estate leasing services, and lending facilities to medical and adult-use cannabis licensees under management service agreements.

However, given that in the investing world past performance is never necessarily an indication of future performance, which of these pot giants  is a better buy right now. So, how do Canopy Growth’s prospects stack up against Curaleaf’s?  Let’s find out.

Canopy Growth continues to remain unprofitable

Canadian cannabis companies have been negatively impacted by a slew of industry-wide issues. These include lower than expected demand due to the slow rollout of retail stores in major Canadian provinces, as well as a thriving black market. This in turn has led to high inventory levels, massive write-downs and widening losses. An increase in competition has exacerbated these companies’ business challenges.

In the quarter ended December 31,  Canopy Growth reported sales of CAD$153 million, which represented a 23%  increase  23% year over year. The revenue growth allowed Canopy to reduce its EBITDA losses to CAD$68 million, compared to CAD$97 million in EBITDA losses  in the prior-year period.

While Canopy Growth has burnt through significant cash in recent quarters, it has a strong liquidity position because the company is backed by U.S. beverage heavyweight Constellation Brands (STZ). Over the last handful of years, , Constellation Brands has pumped  more than  $4 billion into Canopy Growth for a 38.6% stake. Constellation’s ex-CFO David Klein is now the  CEO of Canopy growth. He has focused on reducing costs in the past year.

Canopy Growth will also benefit from Constellation’s beverage expertise, allowing it to launch a wide range of cannabis-infused beverages that are high-margin products. The company is already expanding its portfolio of Cannabis 2.0 products, which  include edibles and vapes in addition to beverages.

Curaleaf is growing top line at a rapid pace

Curaleaf is one of the largest cannabis retailers in the U.S., where it operates more than  100 dispensaries. It is also the largest pot company in terms of annual sales. Curaleaf has a presence in 23 states in the U.S. and leads the market in states that include  New York, New Jersey, Connecticut, Vermont, Massachusetts, Maryland, Pennsylvania and North Dakota.

CURLF also claims to be among the top three retailers in Florida, Arizona, Maine and Illinois. The prospect of cannabis legalization at the federal level in the U.S. will be a key driver of top-line growth for Curaleaf in the coming decade. Curaleaf recently acquired EMMAC Life Sciences, which is Europe’s largest vertically integrated marijuana company.

In the quarter ended December 31, Curaleaf reported sales of $230.3 million, representing an increase of 205% year over year. In 2020, its sales were up 186%, totaling $626.6 million. While Curaleaf is still not profitable, it has posted seven consecutive quarters of positive EBITDA. And in  the fourth quarter of 2020, its EBITDA soared to $53.8 million compared to just $13.8 million in the prior-year period.

The verdict

Given Curaleaf’s enviable growth rates, rising profit margins and massive size, we think it’s a no-contest when compared to its counterpart north of the border. If and when cannabis legalization takes place in the U.S., Curaleaf’s already established presence will allow it to gain traction in what will be the largest marijuana market in the world.

Further, despite Curaleaf’s higher revenue growth, the stock is trading at a lower multiple compared to Canopy Growth. Curaleaf ‘s stock is valued at a market cap of $9 billion, which means its trading at a trailing price to sales multiple of 14.3x. In comparison,  the trailing price to sales multiple for Canopy Growth is twice as high at 32x, making Curaleaf a much better bet.


CGC shares were trading at $27.52 per share on Monday morning, up $0.11 (+0.40%). Year-to-date, CGC has gained 11.69%, versus a 12.11% rise in the benchmark S&P 500 index during the same period.


About the Author: Aditya Raghunath


Aditya Raghunath is a financial journalist who writes about business, public equities, and personal finance. His work has been published on several digital platforms in the U.S. and Canada, including The Motley Fool, Finscreener, and Market Realist. More...


More Resources for the Stocks in this Article

TickerPOWR RatingIndustry RankRank in Industry
CGCGet RatingGet RatingGet Rating
CURLFGet RatingGet RatingGet Rating

Most Popular Stories on StockNews.com


:  |  News, Ratings, and Charts

Top 10 Value Stocks

The S&P 500 (SPY) has shown mixed results in the last week, but if you are a value investor, then yesterday was a big day. That’s when we revealed to our readers the fatal flaws of traditional value investing and the solution to this problem—our Top 10 Value Stocks strategy. Read on below to find out more about this 3-step process and its +38.63% annual returns…

:  |  News, Ratings, and Charts

4 Top-Rated Tech Stocks to Enhance Your Portfolio

The investor rotation away from technology stocks is expected to be short-lived owing to the unabated demand for advanced technology products and services. Therefore, we think some of the biggest names in the tech industry, specifically Intel (INTC), International Business Machines Corporation (IBM), Panasonic (PCRFY), and Canon (CAJ) are solid bets at their current price levels. Read on for an explanation.

:  |  News, Ratings, and Charts

2 Casino Stocks Wall Street Loves

The easing of pandemic distancing restrictions facilitated by mass vaccinations is allowing casinos and related entertainment companies to reopen at 40-50% capacity. This, coupled with the rising popularity of online gambling, is fostering optimism among Wall Street analysts about the upside potential of Penn National Gaming (PENN) and Melco Resorts & Entertainment (MLCO). Read on.

:  |  News, Ratings, and Charts

4 Buy-Rated Financial Stocks to Snatch Up in May

Financial sector stocks have been making an impressive comeback in lockstep with the economy’s recovery. So, we think investing in the stocks of fundamentally sound Goldman Sachs (GS), Lazard (LAZ), Piper Sandler (PIPR), and Cowen (COWN) could pay off handsomely in the near term.

:  |  News, Ratings, and Charts

2 Casino Stocks Wall Street Loves

The easing of pandemic distancing restrictions facilitated by mass vaccinations is allowing casinos and related entertainment companies to reopen at 40-50% capacity. This, coupled with the rising popularity of online gambling, is fostering optimism among Wall Street analysts about the upside potential of Penn National Gaming (PENN) and Melco Resorts & Entertainment (MLCO). Read on.

Read More Stories

More Canopy Growth Corporation (CGC) News View All

Event/Date Symbol News Detail Start Price End Price Change POWR Rating
Loading, please wait...
View All CGC News